中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2014年
17期
59-61
,共3页
心可舒%乙胺碘呋酮%心房纤颤
心可舒%乙胺碘呋酮%心房纖顫
심가서%을알전부동%심방섬전
Xinkeshu tablets%Amiodarone%Atrial fibrillation
目的:探讨心可舒联合乙胺碘呋酮治疗冠心病快速心房纤颤的临床疗效。方法病例选自我院2011年12月~2013年12月收治的冠心病快速心房纤颤患者共90例,分为两组,其中对照组(n=45)单纯给予乙胺碘呋酮治疗,观察组(n=45)采取心可舒联合乙胺碘呋酮治疗,观察并比较两组临床治疗效果及不良反应发生情况。结果观察组总有效率为91.11%,显著高于对照组的77.78%,两组比较差异有统计学意义(P<0.05);观察组不良反应发生率为6.66%,显著低于对照组的26.67%,两组比较差异有统计学意义(P<0.05)。结论心可舒联合乙胺碘呋酮治疗冠心病快速心房纤颤疗效确切,可有效控制心室率,改善临床症状,且不良反应发生率低,安全性好,具有较好的临床应用价值。
目的:探討心可舒聯閤乙胺碘呋酮治療冠心病快速心房纖顫的臨床療效。方法病例選自我院2011年12月~2013年12月收治的冠心病快速心房纖顫患者共90例,分為兩組,其中對照組(n=45)單純給予乙胺碘呋酮治療,觀察組(n=45)採取心可舒聯閤乙胺碘呋酮治療,觀察併比較兩組臨床治療效果及不良反應髮生情況。結果觀察組總有效率為91.11%,顯著高于對照組的77.78%,兩組比較差異有統計學意義(P<0.05);觀察組不良反應髮生率為6.66%,顯著低于對照組的26.67%,兩組比較差異有統計學意義(P<0.05)。結論心可舒聯閤乙胺碘呋酮治療冠心病快速心房纖顫療效確切,可有效控製心室率,改善臨床癥狀,且不良反應髮生率低,安全性好,具有較好的臨床應用價值。
목적:탐토심가서연합을알전부동치료관심병쾌속심방섬전적림상료효。방법병례선자아원2011년12월~2013년12월수치적관심병쾌속심방섬전환자공90례,분위량조,기중대조조(n=45)단순급여을알전부동치료,관찰조(n=45)채취심가서연합을알전부동치료,관찰병비교량조림상치료효과급불량반응발생정황。결과관찰조총유효솔위91.11%,현저고우대조조적77.78%,량조비교차이유통계학의의(P<0.05);관찰조불량반응발생솔위6.66%,현저저우대조조적26.67%,량조비교차이유통계학의의(P<0.05)。결론심가서연합을알전부동치료관심병쾌속심방섬전료효학절,가유효공제심실솔,개선림상증상,차불량반응발생솔저,안전성호,구유교호적림상응용개치。
Objective To explore the clinical effect of combined Xinkeshu tablets and amiodarone in patients with coronary heart disease of fast atrial fibrillation.Methods90 cases with coronary heart disease of fast atrial fibrillation treated in our hospital from December 2011 to December 2013 were selected,that were divided into two group, patients in control group(n=45) received amiodarone treatment, observation group(n=45) received Xinkeshu and amiodarone treatment, clinical effect and adverse events were compared before and after being treated.ResultsThe effective treatment rate of observation group was 91.11%, The date was significantly higher than the 77.78% of control group, differences were statistically significant (P<0.05),The adverse reactions rate of observation group was 6.66%, the date was significantly lower than 26.67% of control group, Differences were statistically significant (P<0.05).ConclusionThe combined treatment of Xinkeshu tablets and amiodarone could obtain better curative effect in the treatment of coronary heart disease of fast atrial fibrillation, and can effectively improve the clinical symptoms and clinical treatment outcomes, and it has a low incidence of adverse reactions and drug safety,and is worth of clinical application and promotion.